Shape Therapeutics, Inc., a Seattle, WA-based development-stage biotechnology company focused on RNA-editing gene therapy, raised $35.5M in Series A financing.
The round was led by New Enterprise Associates (NEA), with participation from CureDuchenne Ventures.
The new capital will enable the company to extend its portfolio of intellectual property, recruit and hire top scientific talent and advance its RNA and protein targeting platforms focused on curing human diseases.
Founded by Prashant Mali, Ph.D., Francois Vigneault, Ph.D., and John Suliman, Shape Therapeutics is creating RNA and protein targeting platforms focused on the cure of human diseases. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). The RNAfix™ technology allows for the editing of RNA using natural human cellular machinery, limiting the risk associated with immunogenicity, cellular toxicity, or off-target DNA editing.
The company has a satellite site opening in Cambridge, Massachusetts.
The Series A financing coincides with the formation of a Scientific Advisory Board comprised of global experts in genomics, bioengineering, and gene editing, including George Church Ph.D., James Collins Ph.D., and Don Cleveland Ph.D. The scientific advisory board will serve as strategic advisors and ensure that the research and development of its platforms meet the highest standards of scientific merit.